8 Results for "

LOK

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "LOK" in MCE Product Catalog:

  • Isoforms Recommended:
4
4 Cited Publications
Cat. No.: HY-108333
CAS No.: 956613-01-7
Purity:  98.05%
Target:  

Ser/Thr Kinase

Research Areas:  

Cardiovascular Disease Cancer

SB-633825 is a potent and ATP-competitive inhibitor of TIE2, LOK (STK10) and BRK with IC50s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesis .
loading...
    loading...
Cat. No.: HY-111553
CAS No.: 2088323-16-2
Purity:  99.71%
Target:  

EGFR

Research Areas:  

Cancer

TAS0728 is a potent, selective, orally active, irreversible and covalent-binding HER2 inhibitor, with an IC50 of 13 nM. TAS0728 also shows IC50s of 4.9, 8.5, 31, 65, 33, 25 and 86 nM for BMXHER4BLK、EGFR、JAK3SLK and LOK respectively. Furthermore, TAS0728 exhibits robust and sustained inhibition of the phosphorylation of HER2, HER3, and downstream effectors .
loading...
    loading...
Cat. No.: HY-RS13920
Research Areas:  

Others

STK10 Human Pre-designed siRNA Set A contains three designed siRNAs for STK10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS17559
Research Areas:  

Others

Stk10 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Stk10 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-P73282
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Serine/threonine-protein kinase 10; STK10; LOK
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-108333R
CAS No.: 956613-01-7
SB-633825 (Standard) is the analytical standard of SB-633825 (HY-108333). This product is intended for research and analytical applications. SB-633825 is a potent and ATP-competitive inhibitor of TIE2, LOK (STK10) and BRK with IC50s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesis .
loading...
    loading...
Cat. No.: HY-179535
CAS No.: 1958081-87-2
Axl-IN-21 is an orally active and selective AXL inhibitor (Kd = 2.7 nM, IC50 = 4.0 nM). Axl-IN-21 displays kinase selectivity and retains strong activity against cancer-related mul-kinases (Mer with Kd = 1.4 nM, DDR1 with IC50 = 22.2 nM, HIPK4 with Kd = 11.0 nM and LOK with Kd =10 nM). Axl-IN-21 overcomes tumor microenvironment-driven resistance by blocking CAF-derived GAS6-induced AXL/STAT3/ABCG1 signaling, restoring chemosensitivity and inhibiting drug efflux in gastric cancer (GC). Axl-IN-21 suppresses TGF-β1-induced epithelial-mesenchymal transition (EMT), migration, and invasion in MDA-MB-231 cells. Axl-IN-21 exhibits no significant cytotoxicity in non-cancerous cells. Axl-IN-21 can be research for triple negative breast cancer and gastric cancer [1] [2] .
loading...
    loading...
Cat. No.: HY-18909
CAS No.: 1157857-36-7
Target:  

Src Bcr-Abl Pyk2 p38 MAPK c-Kit

Research Areas:  

Others

Multi-kinase-IN-11 (Compound 1a) is a DFG-out conformation-targeted multi-kinase inhibitor, including SRC, LCK, ABL, PYK2, CSK, HCK, P38 and C-KIT. Multi-kinase-IN-11 serves as a scaffold for the preparation of fluorescently labeled binding probes and affinity matrices .
loading...
    loading...